Progenics And Cytogen Announce Progress On Vaccine And Antibody Therapies For Prostate Cancer

Progenics Pharmaceuticals, Inc. and Cytogen Corporation have announced new findings on immune therapies which may play a future role in the treatment of prostate and other cancers. The therapies are directed against Prostate Specific Membrane Antigen (PSMA), a molecular cancer marker that is abundantly expressed on the surface of prostate cancer cells. The developments, presented Read more about Progenics And Cytogen Announce Progress On Vaccine And Antibody Therapies For Prostate Cancer[…]

Letters Of Intent Signed For Barr To Acquire Rights To Galen’s Loestrin(r) Oral Contraceptive Product

Barr Laboratories, Inc. and Galen Holdings PLC have announced that they have signed a letter of intent for Barr to acquire the exclusive rights in the United States and Canada for Loestrin(R) and Loestrin(R) FE oral contraceptive products. The proposed transaction also would include a settlement of pending litigation between Barr and Galen regarding Galen’s Read more about Letters Of Intent Signed For Barr To Acquire Rights To Galen’s Loestrin(r) Oral Contraceptive Product[…]

Approvable Letter Received For Uroxatral

SkyePharma PLC and Sanofi-Synthelabo have received an “approvable letter” from the US FDA for UroXatral (once-daily formulation of alfuzosin) for the symptomatic treatment of benign prostatic hyperplasia. The formulation utilizes SkyePharma’s proprietary oral drug delivery technology, GEOMATRIX. The New Drug Application for UroXatral was submitted in December 2000 in the United States. Michael Ashton, SkyePharma’s Read more about Approvable Letter Received For Uroxatral[…]

AHP And Aventis Pharma Finalise HRT Agreement

American Home Products Corporation and Aventis Pharma have renegotiated their licensing agreement for trimegestone, a modern progestational molecule originated by Aventis for hormone replacement therapy. Under the new agreement, Wyeth-Ayerst Laboratories, the pharmaceutical division of AHP, has exclusive development and worldwide marketing rights for trimegestone for all indications and formulations except transdermal products. The rights Read more about AHP And Aventis Pharma Finalise HRT Agreement[…]